{"ORPHApacket":[{"ORPHApacketID":"102379","date":"2019-12-05 22:05:25","version":"1.3.1 \/ 4.1.7 [2019-11-24] (orientdb version)","copyright":"Orphanet (c) 2019","ORPHA":"102379","Name":[{"lang":"en","label":"Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent"}],"PURL":"http:\/\/www.orpha.net\/ORDO\/Orphanet_102379","DisorderType":[{"Name":[{"lang":"en","label":"Disease"}],"PURL":"http:\/\/www.orpha.net\/ORDO\/Orphanet_377788"}],"SubClassOfList":[{"Disorder":[{"Name":[{"lang":"en","label":"Therapy related acute myeloid leukemia and myelodysplastic syndrome"}],"ORPHA":"86846","PURL":"http:\/\/www.orpha.net\/ORDO\/Orphanet_86846"}]}],"TextSection":[{"Name":[{"lang":"en","label":"Definition"}],"Contents":"A subgroup of therapy-related myeloid neoplasms (t-MN), associated with a treatment of an unrelated neoplastic or autoimmune disease with cytotoxic agents, like cyclophosphamid, platins, melphalan and others. The neoplastic cells typically harbor unbalanced aberrations of chromosomes 5 and 7 (monosomy 5\/del(5q) and monosomy 7\/del(7q)) or a complex karyotype. It usually presents with multilineage dysplasia and cytopenias 5-10 years after exposure, with symptoms related to the degree of bone marrow failure and the corresponding cytopenia (fatigue, bleeding and bruising, recurrent infections, bone pain)."}],"SynonymList":[{"count":"1","Synonym":[{"lang":"en","label":"AML and myelodysplastic syndromes related to alkylating agent"}]}]}]}